BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

PR Pharmaceuticals, Inc. Release: New Patent Issued To The University of Pittsburgh For 2-Methoxyestradiol


3/16/2006 11:10:16 AM

FORT COLLINS, Colo., March 16 /PRNewswire/ -- PR Pharmaceuticals Inc. (PRP), announced today the issuance of U.S. Patent No. 6,998,395 covering 2-methoxyestradiol (2ME) for the treatment of diabetes. The patent which is assigned to the University of Pittsburgh has been exclusively licensed to PRP. The drug, known as PulmoLAR(TM), containing 2ME as active ingredient, is currently developed by PRP for the treatment of pulmonary arterial hypertension (PAH).

"We have demonstrated in an animal model of the metabolic syndrome that treatment with 2ME can significantly attenuate much of the pathology associated with the metabolic syndrome," said Edwin K. Jackson Ph.D., Professor at the University of Pittsburgh School of Medicine and co-inventor of this recently issued patent. "Treatment with 2ME resulted in reduced glycated hemoglobin levels, improved response to an oral glucose tolerance test and reduced kidney damage as shown by a significant reduction in proteinuria. These data are very encouraging as we continue to explore the mechanism of action and gain a deeper understanding of the potential applications of this novel compound."

"The data generated to support this patent suggest 2ME has potential in areas beyond Pulmonary Hypertension," said Dr. Claude Piche, PRP's vice-president of Clinical Development and Regulatory Affairs. "We continue to investigate this and other potential uses of 2ME and further expand our IP portfolio."

About PulmoLAR(TM)

The active ingredient in PulmoLAR is 2ME, an endogenous non-estrogenic metabolite of estradiol. 2ME has multiple mechanisms of action, many of which are relevant to PAH. In vitro studies have demonstrated 2ME reduces endothelial cell production of endothelin-1 and increases synthesis of prostacyclin. 2ME is also a potent antiproliferative agent. PulmoLAR is PRP's proprietary sustained release injectable formulation. Phase I studies with PulmoLAR are planned for 2006.

About PR Pharmaceuticals, Inc.

PRP is a biopharmaceutical company developing, manufacturing and commercializing bioactive compounds in its injectable sustained-release technologies. The Company has a significant Intellectual Property position in the encapsulation of large molecules such as proteins and peptides as well as encapsulation of classic small molecules into biodegradable microparticles. PRP is applying compelling and patented technology to create a diverse range of candidate pharmaceutical products to address unmet medical needs. For more information, please see www.prpharm.com

PulmoLAR(TM) is a trademark of PR Pharmaceuticals, Inc.

PR Pharmaceuticals Inc.

CONTACT: Dr. Claude Piche of PR Pharmaceuticals Inc., +1-970-484-5560



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES